BAM
AGIO icon

Belpointe Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Belpointe Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,518
Closed -$888K – 498
2018
Q3 		$888K Buy
+11,518
New +$927K 0.14% 145
2018
Q1 		– Sell
-11,500
Closed -$657K – 350
2017
Q4 		$657K Sell
11,500
-7,231
-39% -$455K 0.14% 159
2017
Q3 		$1.25M Buy
+18,731
New +$1.13M 0.29% 76

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Belpointe Asset Management's AGIO Position: Q4 2018 in Review

Belpointe Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 11,518 shares — an estimated $888K sold.

Belpointe Asset Management first reported a position in AGIO in Q3 2017 and held it in 3 quarters. The position peaked at $1.25M in Q3 2017. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

  • Belpointe Asset Management reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Belpointe Asset Management sold 11,518 Agios Pharmaceuticals shares in Q4 2018, an estimated $888K.
  • Belpointe Asset Management first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Belpointe Asset Management's Agios Pharmaceuticals position peaked at $1.25M in Q3 2017.
  • 196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Belpointe Asset Management's 13F filing for Q4 2018, filed 6 Mar 2019.